SAN DIEGO, June 2 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. today announced that IVS Associates, Inc., the independent Inspector of Elections for the Company’s Annual Meeting of Stockholders held May 27, 2009, has completed its preliminary tabulation of shareholder votes. The preliminary tabulation indicates that shareholders voted to re-elect eight of the Company’s current Directors to Amylin’s Board of Directors - Adrian Adams, Steven R. Altman, Teresa Beck, Daniel M. Bradbury, Karin Eastham, Dr. James R. Gavin III, Dr. Jay S. Skyler, and Joseph P. Sullivan, as well as voted to elect its two new independent nominees, Paul N. Clark and Paulo F. Costa. In addition, Dr. Kathleen Behrens and Dr. Alexander J. Denner, Director candidates nominated by Eastbourne Capital Management, L.L.C. and Carl Icahn, respectively, were also elected to the Board. Joseph C. Cook, Jr., Amylin’s Chairman, and James N. Wilson, Amylin’s Lead Independent Director, were not re-elected to the Board.
Separately, IVS also reported the preliminary tabulation of the other proposals voted on at the Annual Meeting:
The Company issued the following statement:
Voting results on Director elections and all proposals will be finalized once they are certified by the Inspector following a customary review and challenge period. A final tally of the votes will be published in the Company’s next quarterly report on Form 10-Q which will be filed with the Securities and Exchange Commission in August.
About Amylin
Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin’s research and development activities leverage the Company’s expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at www.amylin.com.
Forward Looking Statements
This press release contains forward-looking statements about Amylin, which involve risks and uncertainties. Our actual results could differ materially from those discussed herein due to a number of risks and uncertainties, including risks that BYETTA, SYMLIN or exenatide once weekly may be affected by competition, unexpected new data, safety and technical issues, or manufacturing and supply issues; risks that our clinical trials will not be completed when planned, may not replicate previous results or achieve desired end-points; risks that our preclinical studies may not be predictive; risks that our NDAs for product candidates or sNDAs for label expansion requests may not be submitted timely or receive FDA approval; and other risks inherent in the drug development and commercialization process. Commercial and government reimbursement and pricing decisions and the pace of market acceptance may also affect the potential for BYETTA, SYMLIN or exenatide once weekly. These and additional risks and uncertainties are described more fully in the Company’s most recently filed Form 10-Q. Amylin disclaims any obligation to update these forward-looking statements.
CONTACT: Alice Izzo, Executive Director, Corporate Affairs, Amylin
Pharmaceuticals, Inc., +1-858-642-7272, alice.izzo@amylin.com; Steve
Frankel, or Averell Withers, both of Joele Frank, Wilkinson Brimmer
Katcher, +1-212-355-4449
Web site: http://www.amylin.com/
